Dupixent started 2023 the way it ended 2022: at the top. The severe asthma treatment had the largest impressions share of voice (SOV) among Rx and over-the-counter pharma brands in January, totaling ...

In the pharma TV ad race, Dupixent and Humira are trading the top spending spots—again. Sanofi and Regeneron’s asthma and eczema drug climbed back to No. 1 in May, while AbbVie’s blockbuster ...

Lack of insurance coverage continues to be the most commonly cited barrier to use, while out-of-pocket costs have become a growing concern amongst dermatologists. Those with ample experience with the ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Sanofi CEO Paul Hudson has been on the job since September, but he’s already learned how to get Wall Street’s attention. Back in December, after Hudson boldly announced that he’d set the annual ...

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Allergies are an inconvenience at best and deadly at worst. But despite around one in three adults and one in four children having seasonal allergies, food allergies or eczema, according to statistics ...